Table A1.

Initial Management Strategy by Baseline Disease and Patient Demographics Characteristics

Characteristic	Observation		Rituximab Monotherapy		Chemotherapy		Rituximab Chemotherapy		XRT		Clinical Trial		Other		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
No. of patients	484		378		86		1,415		154		167		44		2,728
FLIPI
Low, 0–1	156	21.3	89	12.1	19	2.6	334	45.6	92	12.6	33	4.5	10	1.4	733	100
Intermediate, 2	135	20.0	92	13.6	25	3.7	340	50.4	10	1.5	64	9.5	9	1.3	675	100
High, 3–5	59	9.2	90	14.0	22	3.4	404	62.8	5	0.8	52	8.1	11	1.7	643	100
Unknown	134	19.8	107	15.8	20	3.0	337	49.8	47	6.9	18	2.7	14	2.1	677	100
Histology by grade
1	282	24.6	193	16.8	34	3.0	459	40.0	76	6.6	82	7.1	21	1.8	1,147	100
2	115	15.0	108	14.1	25	3.3	404	52.7	46	6.0	54	7.0	14	1.8	766	100
3	47	9.4	41	8.2	17	3.4	355	70.9	13	2.6	24	4.8	4	0.8	501	100
Multiple histology	2	3.8	3	5.8	2	3.8	44	84.6	0	0.0	1	1.9	0	0.0	52	100
Unknown	38	14.5	33	12.6	8	3.1	153	58.4	19	7.3	6	2.3	5	1.9	262	100
Stage
I	136	28.7	61	12.9	12	2.5	144	30.4	111	23.4	0	0.0	10	2.1	474	100
II	84	20.1	70	16.8	16	3.8	209	50.1	24	5.8	6	1.4	8	1.9	417	100
III	148	18.5	121	15.1	29	3.6	430	53.6	4	0.5	59	7.4	11	1.4	802	100
IV	115	11.4	123	12.1	28	2.8	620	61.2	12	1.2	101	10.0	14	1.4	1,013	100
Unknown	1	4.5	3	13.6	1	4.5	12	54.5	3	13.6	1	4.5	1	4.5	22	100
Region
Midwest	149	17.3	118	13.7	18	2.1	435	50.5	59	6.8	69	8.0	14	1.6	862	100
Northeast	136	29.0	63	13.4	15	3.2	182	38.8	28	6.0	40	8.5	5	1.1	469	100
Southeast	109	13.3	109	13.3	40	4.9	474	57.7	42	5.1	33	4.0	15	1.8	822	100
Southwest	35	16.7	18	8.6	6	2.9	131	62.7	9	4.3	4	1.9	6	2.9	209	100
West	55	15.0	70	19.1	7	1.9	193	52.7	16	4.4	21	5.7	4	1.1	366	100
Site type
Academic	112	20.9	61	11.4	18	3.4	238	44.5	30	5.6	70	13.1	6	1.1	535	100
Community	372	17.0	317	14.5	68	3.1	1,177	53.7	124	5.7	97	4.4	38	1.7	2,193	100

Abbreviations: FLIPI, Follicular Lymphoma International Prognostic Index; XRT, external-beam radiotherapy.